PUBLISHER: The Business Research Company | PRODUCT CODE: 2106472
PUBLISHER: The Business Research Company | PRODUCT CODE: 2106472
An antibody discovery service is a specialized research service focused on the identification, development, and optimization of antibodies for therapeutic, diagnostic, and scientific research applications. These services help accelerate development processes, increase the likelihood of successful outcomes, and support the creation of targeted therapies and precision medicine solutions.
The primary services offered within antibody discovery services include target identification and validation, antibody engineering and optimization, antigen design and production, immunization and host management, and other related services. Target identification and validation is the process of recognizing biological targets and verifying their potential for antibody-based therapeutic development. These services support antibody categories such as monoclonal, polyclonal, bispecific, and other antibody types, while leveraging technologies including phage display technology, hybridoma technology, single-cell technology, recombinant deoxyribonucleic acid technology, next-generation sequencing, and artificial intelligence-based discovery. Their applications cover oncology, infectious diseases, immunology, and other fields, and they are utilized by end users including pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations.
Tariffs are influencing the antibody discovery service market by increasing expenses associated with importing specialized laboratory reagents, sequencing platforms, and high-end bioprocessing instruments used in antibody research and development. This is delaying research timelines and elevating operational costs for pharmaceutical companies, biotechnology firms, and contract research organizations, particularly in import-dependent regions such as Asia-Pacific and Europe. Segments like antibody engineering, high-throughput screening, and next-generation sequencing services are most affected due to reliance on globally sourced tools and consumables. However, tariffs are also fostering the development of localized biotech supply chains, boosting investment in domestic research infrastructure, and expanding regional CRO capabilities, thereby strengthening long-term innovation capacity.
The antibody discovery services market size has grown rapidly in recent years. It will grow from $2.9 billion in 2025 to $3.24 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing demand for targeted biologic therapies, expansion of monoclonal antibody drug development, rising outsourcing of R&D by pharmaceutical companies, advancements in hybridoma and phage display techniques, growth in biotechnology research funding.
The antibody discovery services market size is expected to see rapid growth in the next few years. It will grow to $5.07 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to increasing adoption of AI-powered drug discovery platforms, rising demand for personalized and precision medicine, expansion of biologics and biosimilar development pipelines, growing use of automation in antibody screening processes, and increasing collaborations between biotech companies and CRO service providers. Major trends in the forecast period include automation of high-throughput antibody discovery workflows using robotic systems, cloud-based bioinformatics integration for antibody sequence analysis and optimization, digital twin modeling for antibody-antigen interaction simulation, Industry 4.0-enabled smart biolab automation for accelerated discovery pipelines, and rising demand for precision medicine-driven customized antibody development services.
The increasing adoption of precision medicine and targeted therapies is expected to drive the expansion of the antibody discovery services market going forward. Precision medicine and targeted therapies refer to medical approaches that customize treatments based on individual genetic, molecular, and clinical characteristics to enhance outcomes and minimize adverse effects. The adoption of precision medicine and targeted therapies is rising due to the increasing number of personalized drug approvals, reflecting strong innovation in targeted treatment development. Antibody discovery services facilitate the advancement of precision medicine and targeted therapies by enabling the creation of highly specific antibodies that accurately target disease-related biomarkers and biological pathways, thereby improving treatment precision and effectiveness. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, compared to just six approvals recorded in 2022. Therefore, the increasing adoption of precision medicine and targeted therapies is driving the growth of the antibody discovery services market.
Key companies operating in the antibody discovery services market are focusing on developing advanced solutions, such as AI-driven antibody discovery workflows, to streamline candidate screening, improve binding validation efficiency, and accelerate lead selection workflows. AI-driven antibody discovery workflows use artificial intelligence and machine learning to accelerate the identification, screening, and optimization of antibody candidates, improving prediction accuracy, reducing development timelines, and enhancing overall research efficiency. For example, in May 2026, Nuclera, a UK-based biotechnology company, launched its antibody triage service to support AI-driven antibody discovery workflows. The service utilizes 96-plex binary cell-free expression and binding assays to screen full-length antibody libraries in parallel and rapidly identify confirmed binders from large AI-generated candidate pools. The platform also integrates Surface Plasmon Resonance (SPR) analysis for binding kinetics evaluation, enabling researchers to reduce non-binder validation costs, improve workflow efficiency, and accelerate progression from antibody hit generation to lead selection.
In December 2023, Danaher Corporation, a US-based life sciences company, acquired Abcam plc for an undisclosed amount. Through this acquisition, Danaher Corporation aimed to strengthen its life sciences portfolio by integrating Abcam plc's comprehensive antibody reagent capabilities, enhancing support for biopharmaceutical research, and advancing antibody discovery workflows. Abcam plc is a UK-based biotechnology company that provides research-grade antibodies and related reagents for life sciences research, diagnostics, and drug discovery applications.
Major companies operating in the antibody discovery services market are Thermo Fisher Scientific Inc., WuXi AppTec Co. Ltd., Lonza Group AG, Charles River Laboratories, WuXi Biologics (Cayman) Inc., Eurofins Discovery, Evotec SE, GenScript Biotech Corporation, Abcam plc, Syngene International Limited, Twist Bioscience, Sino Biological Inc., OmniAb Inc., FairJourney Biologics S.A., Abzena, Biocytogen Pharmaceuticals (Beijing) Co. Ltd., Genoway S.A., Aurigene Pharmaceutical Services Limited, Adimab LLC, Harbour BioMed Limited, Absolute Biotech, Abnova Corporation, Biointron Biological Inc., Creative Biolabs Inc., ProteoGenix SAS, Integral Molecular Inc., Ablexis LLC, Isogenica Limited, MabDiscovery GmbH
North America was the dominant region in the antibody discovery services market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in antibody discovery services report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the antibody discovery services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The antibody discovery services market consists of revenues earned by entities by providing services such as hybridoma development, phage display screening, single B-cell screening, antibody characterization, and profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The antibody discovery services market research report is one of a series of new reports from The Business Research Company that provides antibody discovery services market statistics, including antibody discovery services industry global market size, regional shares, competitors with a antibody discovery services market share, detailed antibody discovery services market segments, market trends and opportunities, and any further data you may need to thrive in the antibody discovery services industry. This antibody discovery services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Antibody Discovery Services Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses antibody discovery services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for antibody discovery services ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antibody discovery services market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.